Literature DB >> 18462709

Lack of D2 receptor mediated regulation of dopamine synthesis in A11 diencephalospinal neurons in male and female mice.

Samuel S Pappas1, Bahareh Behrouz, Kelly L Janis, John L Goudreau, Keith J Lookingland.   

Abstract

Dopamine (DA) neurons comprising the A11 diencephalospinal system represent the major source of DA innervation to the spinal cord. These neurons project axons throughout the rostrocaudal extent of the spinal cord, terminating predominantly in the dorsal horn. Loss of DA-mediated sensorimotor function in the lumbar segment of spinal cord is implicated in the etiology of Restless Legs Syndrome (RLS), which is more prevalent in females as compared with males. The purpose of the present study was to compare the density (DA concentrations) and catabolic activity (3,4-dihydroxyphenylacetic acid; DOPAC) of A11 DA neurons innervating the lumbar spinal cord of male and female C57/BL6 mice, and to determine if there is a sexual difference in the regulation of these neurons by D2 autoreceptor-mediated mechanisms. DA concentrations in the lumbar spinal cord were higher in males, suggesting a greater A11 DA innervation as compared with females, whereas there was no sexual difference in the activity (DOPAC/DA ratio) of these DA neurons under basal conditions. Blockade of D2 receptors with raclopride caused a significant increase in the DOPAC/DA ratio in the striatum and nucleus accumbens in both males and females, but had no effect in the spinal cord. Blockade of neuronal impulse flow and DA release with gamma-butyrolactone (GBL) increased DA concentrations in the spinal cord, but this increase was not prevented by pretreatment with the D2 agonist quinelorane. These results are consistent with the conclusion that A11 diencephalospinal DA neurons in both males and females lack presynaptic synthesis modulating D2 autoreceptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18462709     DOI: 10.1016/j.brainres.2008.03.010

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

Review 1.  Restless legs syndrome: pathophysiology, clinical presentation and management.

Authors:  Claudia Trenkwalder; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2010-06       Impact factor: 42.937

2.  Neonatal androgen-dependent sex differences in lumbar spinal cord dopamine concentrations and the number of A11 diencephalospinal dopamine neurons.

Authors:  Samuel S Pappas; Chelsea T Tiernan; Bahareh Behrouz; Cynthia L Jordan; S Marc Breedlove; John L Goudreau; Keith J Lookingland
Journal:  J Comp Neurol       Date:  2010-07-01       Impact factor: 3.215

3.  Opioid-mediated regulation of A11 diencephalospinal dopamine neurons: pharmacological evidence of activation by morphine.

Authors:  Samuel S Pappas; Tom Kennedy; John L Goudreau; Keith J Lookingland
Journal:  Neuropharmacology       Date:  2011-05-13       Impact factor: 5.250

Review 4.  Dopamine: a parallel pathway for the modulation of spinal locomotor networks.

Authors:  Simon A Sharples; Kathrin Koblinger; Jennifer M Humphreys; Patrick J Whelan
Journal:  Front Neural Circuits       Date:  2014-06-16       Impact factor: 3.492

5.  Characterization of A11 neurons projecting to the spinal cord of mice.

Authors:  Kathrin Koblinger; Tamás Füzesi; Jillian Ejdrygiewicz; Aleksandra Krajacic; Jaideep S Bains; Patrick J Whelan
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

6.  Monoaminergic control of spinal locomotor networks in SOD1G93A newborn mice.

Authors:  Léa Milan; Grégory Barrière; Philippe De Deurwaerdère; Jean-René Cazalets; Sandrine S Bertrand
Journal:  Front Neural Circuits       Date:  2014-07-04       Impact factor: 3.492

7.  Optogenetic Activation of A11 Region Increases Motor Activity.

Authors:  Kathrin Koblinger; Céline Jean-Xavier; Sandeep Sharma; Tamás Füzesi; Leanne Young; Shane E A Eaton; Charlie Hong Ting Kwok; Jaideep Singh Bains; Patrick J Whelan
Journal:  Front Neural Circuits       Date:  2018-10-11       Impact factor: 3.492

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.